

Razelle Kurzrock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9149101/publications.pdf>

Version: 2024-02-01

720
papers

53,207
citations

1094

112
h-index

2375

198
g-index

727
all docs

727
docs citations

727
times ranked

55205
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 847-856.	1.9	1,787
2	Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2598-2608.	1.9	1,779
3	Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 4491-4499.	3.2	1,158
4	The Biology of Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 1999, 341, 164-172.	13.9	1,126
5	Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. <i>Lancet</i> , The, 2012, 379, 1893-1901.	6.3	856
6	The Molecular Genetics of Philadelphia Chromosome-Positive Leukemias. <i>New England Journal of Medicine</i> , 1988, 319, 990-998.	13.9	798
7	Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. <i>Cancer Treatment Reviews</i> , 2018, 62, 50-60.	3.4	730
8	Autophagy as a target for anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 528-539.	12.5	709
9	Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. <i>Clinical Cancer Research</i> , 2017, 23, 4242-4250.	3.2	704
10	Epstein-Barr Virus and Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 803-821.	3.2	637
11	The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. <i>Clinical Cancer Research</i> , 2016, 22, 259-267.	3.2	537
12	Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2660-2666.	0.8	504
13	The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. <i>Cancer Cell</i> , 2021, 39, 154-173.	7.7	491
14	Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. <i>Lancet Oncology</i> , The, 2012, 13, 773-781.	5.1	487
15	Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. <i>Lancet Oncology</i> , The, 2012, 13, 782-789.	5.1	479
16	Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative. <i>Clinical Cancer Research</i> , 2012, 18, 6373-6383.	3.2	458
17	Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. <i>Nature Medicine</i> , 2019, 25, 744-750.	15.2	443
18	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600E Mutant Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4023-4031.	0.8	430

#	ARTICLE	IF	CITATIONS
19	PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2012, 30, 777-782.	0.8	414
20	Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 3817-3825.	0.8	393
21	International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. <i>Blood</i> , 2017, 129, 1646-1657.	0.6	381
22	Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 464-473.	1.9	377
23	Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 536-542.	0.8	362
24	Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. <i>Nature Medicine</i> , 2019, 25, 751-758.	15.2	362
25	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2019, 20, 518-530.	5.1	362
26	PD-1/PD-L1 immune-checkpoint blockade in B-cell lymphomas. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 203-220.	12.5	358
27	Interleukin-6 and its receptor in cancer. <i>Cancer</i> , 2007, 110, 1911-1928.	2.0	356
28	Sweet's syndrome revisited: a review of disease concepts. <i>International Journal of Dermatology</i> , 2003, 42, 761-778.	0.5	353
29	AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer. <i>Science Translational Medicine</i> , 2015, 7, 314ra185.	5.8	352
30	ATM Mutations in Cancer: Therapeutic Implications. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1781-1791.	1.9	351
31	The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. <i>Molecular Cancer</i> , 2017, 16, 149.	7.9	338
32	Review of precision cancer medicine: Evolution of the treatment paradigm. <i>Cancer Treatment Reviews</i> , 2020, 86, 102019.	3.4	327
33	<i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 558-565.	1.9	311
34	HER2 expression status in diverse cancers: review of results from 37,992 patients. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 157-164.	2.7	310
35	Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1276-1282.	1.9	302
36	Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis. <i>Blood</i> , 1998, 92, 1150-1159.	0.6	285

#	ARTICLE	IF	CITATIONS
37	Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms. <i>JAMA Oncology</i> , 2016, 2, 1452.	3.4	279
38	Cytokines in pancreatic carcinoma. <i>Cancer</i> , 2004, 101, 2727-2736.	2.0	273
39	A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. <i>Nature</i> , 1987, 325, 631-635.	13.7	270
40	PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials. <i>Cancer Research</i> , 2013, 73, 276-284.	0.4	262
41	Philadelphia Chromosome-Positive Leukemias: From Basic Mechanisms to Molecular Therapeutics. <i>Annals of Internal Medicine</i> , 2003, 138, 819.	2.0	259
42	Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. <i>Blood</i> , 2001, 97, 256-263.	0.6	247
43	Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. <i>Cancer</i> , 2009, 115, 5309-5318.	2.0	241
44	Vascular Endothelial Growth Factor and Its Relationship to Inflammatory Mediators: Fig. 1.. <i>Clinical Cancer Research</i> , 2007, 13, 2825-2830.	3.2	237
45	Targeted therapy in non-small-cell lung cancer—is it becoming a reality?. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 401-414.	12.5	231
46	Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of I κ B kinase and nuclear factor I κ B activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. <i>Cancer</i> , 2005, 104, 879-890.	2.0	229
47	Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2012, 30, 2348-2353.	0.8	226
48	Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions. <i>Cancer Treatment Reviews</i> , 2013, 39, 375-387.	3.4	217
49	A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2290-2296.	3.2	215
50	Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. <i>JAMA Oncology</i> , 2018, 4, 1237.	3.4	214
51	Idiopathic multicentric Castleman's disease: a systematic literature review. <i>Lancet Haematology</i> , the, 2016, 3, e163-e175.	2.2	213
52	Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. <i>Blood</i> , 2003, 101, 1692-1697.	0.6	210
53	Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors. <i>Cell Reports</i> , 2014, 6, 377-387.	2.9	210
54	Sweet's syndrome and cancer and cancer. <i>Clinics in Dermatology</i> , 1993, 11, 149-157.	0.8	207

#	ARTICLE	IF	CITATIONS
55	Sweet's syndrome and malignancy. <i>American Journal of Medicine</i> , 1987, 82, 1220-1226.	0.6	204
56	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. <i>Cancer Research</i> , 2016, 76, 3690-3701.	0.4	203
57	Sarcoidosis and malignancy. <i>Clinics in Dermatology</i> , 2007, 25, 326-333.	0.8	201
58	Analysis of <i>NTRK</i> Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for <i>NTRK</i> -Targeted Therapeutics. <i>JCO Precision Oncology</i> , 2018, 2018, 1-20.	1.5	201
59	Siltuximab, a Novel Anti-Interleukin-6 Monoclonal Antibody, for Castleman's Disease. <i>Journal of Clinical Oncology</i> , 2010, 28, 3701-3708.	0.8	195
60	Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19,784 Diverse Solid Tumors. <i>JAMA Oncology</i> , 2016, 2, 1565.	3.4	195
61	Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 2369-2376.	0.8	192
62	Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 1570-1573.	1.6	190
63	<i>BRAF</i> Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i> -Mutant Thyroid Cancer. <i>Thyroid</i> , 2015, 25, 71-77.	2.4	189
64	A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas. <i>Clinical Cancer Research</i> , 2012, 18, 3396-3406.	3.2	188
65	Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses. <i>Clinical Cancer Research</i> , 2014, 20, 4827-4836.	3.2	186
66	<i>RET</i> Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. <i>Clinical Cancer Research</i> , 2017, 23, 1988-1997.	3.2	186
67	Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 2625-2631.	3.2	184
68	HER2 aberrations in cancer: Implications for therapy. <i>Cancer Treatment Reviews</i> , 2014, 40, 770-780.	3.4	184
69	<i>RAS</i> and Leukemia: From Basic Mechanisms to Gene-Directed Therapy. <i>Journal of Clinical Oncology</i> , 1999, 17, 1071-1071.	0.8	182
70	A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease. <i>Clinical Cancer Research</i> , 2013, 19, 3659-3670.	3.2	180
71	Mycobacterial pulmonary infections after allogeneic bone marrow transplantation. <i>American Journal of Medicine</i> , 1984, 77, 35-40.	0.6	179
72	MABp1, a first-in-class true human antibody targeting interleukin-1 in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. <i>Lancet Oncology</i> , The, 2014, 15, 656-666.	5.1	178

#	ARTICLE	IF	CITATIONS
73	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2021, 22, 1290-1300.	5.1	178
74	A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 2458-2465.	3.2	176
75	PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers. <i>PLoS ONE</i> , 2011, 6, e22769.	1.1	174
76	Sweet's Syndrome. <i>American Journal of Clinical Dermatology</i> , 2002, 3, 117-131.	3.3	172
77	Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 5729-5736.	3.2	172
78	Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. <i>Nature Communications</i> , 2020, 11, 4965.	5.8	172
79	FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. <i>Journal of Translational Medicine</i> , 2016, 14, 339.	1.8	167
80	Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. <i>Clinics in Dermatology</i> , 2000, 18, 265-282.	0.8	166
81	Prognostic factor analysis in mycosis fungoides/Sézary syndrome. <i>Journal of the American Academy of Dermatology</i> , 1999, 40, 914-924.	0.6	160
82	Molecular Tumor Board: The University of California San Diego Moores Cancer Center Experience. <i>Oncologist</i> , 2014, 19, 631-636.	1.9	159
83	Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2575-2588.	1.9	156
84	Phase 1b/2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. <i>Cancer</i> , 2011, 117, 1661-1669.	2.0	156
85	A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2010, 16, 1256-1263.	3.2	154
86	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 509.	3.4	154
87	Phase I Study of Epigenetic Modulation with 5-Azacitidine and Valproic Acid in Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2008, 14, 6296-6301.	3.2	153
88	A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 4173-4182.	3.2	153
89	Sweet syndrome in patients with solid tumors. <i>Cancer</i> , 1993, 72, 2723-2731.	2.0	152
90	Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1764-1771.	0.8	149

#	ARTICLE	IF	CITATIONS
91	A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 2192-2204.	3.2	147
92	Development of curcumin as an epigenetic agent. <i>Cancer</i> , 2010, 116, 4670-4676.	2.0	146
93	Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 196-203.	0.8	145
94	Cutaneous paraneoplastic syndromes in solid tumors. <i>American Journal of Medicine</i> , 1995, 99, 662-671.	0.6	144
95	Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 743-752.	1.9	144
96	Phase II Study of R115777, a Farnesyl Transferase Inhibitor, in Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2004, 22, 1287-1292.	0.8	141
97	Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 308-316.	1.9	141
98	Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv253.	3.0	139
99	Nuclear factor- κ B maintains TRAIL resistance in human pancreatic cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2251-2260.	1.9	135
100	Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. <i>Cancer Treatment Reviews</i> , 2014, 40, 883-891.	3.4	131
101	Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. <i>Blood</i> , 2003, 102, 4527-4534.	0.6	129
102	Novel Therapeutic Targets in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1601-1612.	0.5	127
103	A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. <i>American Journal of Medicine</i> , 1990, 89, 663-672.	0.6	126
104	Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 5101-5111.	3.2	126
105	Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. <i>Oncotarget</i> , 2016, 7, 9707-9717.	0.8	123
106	Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas. <i>Clinical Cancer Research</i> , 2009, 15, 3881-3888.	3.2	122
107	A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 5883-5891.	3.2	121
108	Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. <i>Cancer</i> , 1991, 68, 1536-1537.	2.0	120

#	ARTICLE	IF	CITATIONS
109	MS-275 Sensitizes TRAIL-Resistant Breast Cancer Cells, Inhibits Angiogenesis and Metastasis, and Reverses Epithelial-Mesenchymal Transition In vivo. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 3254-3266.	1.9	119
110	Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics. <i>Oncologist</i> , 2011, 16, 497-511.	1.9	119
111	Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. <i>Clinical Cancer Research</i> , 2016, 22, 5497-5505.	3.2	118
112	Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2019, 10, 4018-4025.	0.8	118
113	<i>ARID1A</i> alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. , 2020, 8, e000438.		117
114	TYROSINE KINASE INHIBITORS AND THE DAWN OF MOLECULAR CANCER THERAPEUTICS. <i>Annual Review of Pharmacology and Toxicology</i> , 2005, 45, 357-384.	4.2	115
115	Prospective Blinded Study of <i>BRAF</i> V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. <i>Cancer Discovery</i> , 2015, 5, 64-71.	7.7	115
116	Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse. <i>Clinical Cancer Research</i> , 2010, 16, 1289-1297.	3.2	114
117	Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 6052-6060.	3.2	113
118	The Conundrum of Genetic "Drivers" in Benign Conditions. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw036.	3.0	113
119	Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?. <i>Oncologist</i> , 2010, 15, 130-141.	1.9	110
120	A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 6582-6591.	3.2	109
121	<i>BRAF</i> (V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant <i>BRAF</i> in Cancer Patients Does Not Impair Overall Immune Competency. <i>Clinical Cancer Research</i> , 2012, 18, 2326-2335.	3.2	109
122	Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. <i>JCO Precision Oncology</i> , 2017, 2017, 1-18.	1.5	107
123	A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. <i>Blood</i> , 2007, 109, 4158-4163.	0.6	103
124	Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. <i>Npj Genomic Medicine</i> , 2016, 1, .	1.7	103
125	Pentostatin Therapy of T-Cell Lymphomas With Cutaneous Manifestations. <i>Journal of Clinical Oncology</i> , 1999, 17, 3117-3121.	0.8	102
126	Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. <i>Clinical Cancer Research</i> , 2017, 23, 4716-4723.	3.2	102

#	ARTICLE	IF	CITATIONS
127	Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 479-496.	2.7	101
128	Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid Malignancies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 997-1005.	1.8	100
129	Pancreas Cancer-Associated Weight Loss. <i>Oncologist</i> , 2019, 24, 691-701.	1.9	99
130	<i>BCR</i> Rearrangementâ€“Negative Chronic Myelogenous Leukemia Revisited. <i>Journal of Clinical Oncology</i> , 2001, 19, 2915-2926.	0.8	98
131	Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. <i>Cancer</i> , 1991, 67, 990-996.	2.0	97
132	Cancer: The Road to Amiens. <i>Journal of Clinical Oncology</i> , 2009, 27, 328-333.	0.8	97
133	P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy. <i>Oncotarget</i> , 2013, 4, 705-714.	0.8	96
134	Combined modality therapy for cutaneous T-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 1996, 34, 1022-1029.	0.6	95
135	Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. <i>Cancer Research</i> , 2017, 77, 4238-4246.	0.4	95
136	International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. <i>Blood Advances</i> , 2020, 4, 6039-6050.	2.5	94
137	Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 125-130.	1.1	93
138	Molecular epidemiology, cancer-related symptoms, and cytokines pathway. <i>Lancet Oncology</i> , The, 2008, 9, 777-785.	5.1	92
139	VEGF-A Expression Correlates with <i>TP53</i> Mutations in Nonâ€“Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy. <i>Cancer Research</i> , 2015, 75, 1187-1190.	0.4	92
140	Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. <i>Cancer Research</i> , 2017, 77, 5419-5427.	0.4	92
141	Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. <i>Oncologist</i> , 2017, 22, 631-637.	1.9	91
142	Vasculitis and cancer. <i>Clinics in Dermatology</i> , 1993, 11, 175-187.	0.8	90
143	Equipose Lost: Ethics, Costs, and the Regulation of Cancer Clinical Research. <i>Journal of Clinical Oncology</i> , 2010, 28, 2925-2935.	0.8	89
144	Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 6248-6256.	3.2	89

#	ARTICLE	IF	CITATIONS
145	BAP1: Not just a BRCA1-associated protein. <i>Cancer Treatment Reviews</i> , 2020, 90, 102091.	3.4	89
146	Mucocutaneous paraneoplastic manifestations of hematologic malignancies. <i>American Journal of Medicine</i> , 1995, 99, 207-216.	0.6	88
147	Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. <i>Cancer</i> , 2012, 118, 1422-1428.	2.0	88
148	Risks and Benefits of Phase 1 Oncology Trials, Revisited. <i>New England Journal of Medicine</i> , 2005, 352, 930-932.	13.9	87
149	Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review. <i>Cancer Treatment Reviews</i> , 2017, 52, 12-21.	3.4	87
150	Body Composition, Symptoms, and Survival in Advanced Cancer Patients Referred to a Phase I Service. <i>PLoS ONE</i> , 2012, 7, e29330.	1.1	87
151	Change in Tumor Size by RECIST Correlates Linearly With Overall Survival in Phase I Oncology Studies. <i>Journal of Clinical Oncology</i> , 2012, 30, 2684-2690.	0.8	86
152	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. <i>Oncotarget</i> , 2015, 6, 12809-12821.	0.8	86
153	Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. <i>Seminars in Oncology</i> , 2015, 42, 832-848.	0.8	85
154	Molecular landscape of pancreatic cancer: implications for current clinical trials. <i>Oncotarget</i> , 2015, 6, 4553-4561.	0.8	85
155	Interleukin-10 in Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1997, 26, 251-259.	0.6	84
156	Next generation predictive biomarkers for immune checkpoint inhibition. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 179-190.	2.7	84
157	BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes. <i>PLoS ONE</i> , 2011, 6, e25806.	1.1	83
158	Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. <i>Oncotarget</i> , 2014, 5, 3012-3022.	0.8	82
159	On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1488-1494.	1.9	82
160	Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 948-955.	1.9	81
161	Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2018, 6, 1129-1135.	1.6	81
162	Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 6243-6250.	0.8	79

#	ARTICLE	IF	CITATIONS
163	Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 231-235.	0.6	79
164	Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 3459-3465.	0.8	79
165	PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes. <i>Oncotarget</i> , 2012, 3, 1566-1575.	0.8	79
166	Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies. <i>Clinical Cancer Research</i> , 2009, 15, 7061-7068.	3.2	78
167	Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience. <i>Clinical Cancer Research</i> , 2012, 18, 2922-2929.	3.2	78
168	<i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1397-1404.	1.9	78
169	First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. <i>Clinical Cancer Research</i> , 2016, 22, 1932-1939.	3.2	78
170	Community-acquired methicillin-resistant staphylococcus aureus skin infection: an emerging clinical problem. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, 277-280.	0.6	77
171	Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity. <i>Clinical Cancer Research</i> , 2012, 18, 5796-5805.	3.2	77
172	Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. , 1996, 66, 515-519.		75
173	Erdheim-Chester Disease: Characteristics and Management. <i>Mayo Clinic Proceedings</i> , 2014, 89, 985-996.	1.4	75
174	Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2018, 23, 586-593.	1.9	75
175	Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1991, 77, 291-295.	1.2	74
176	Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2. <i>Clinical Cancer Research</i> , 2009, 15, 5032-5039.	3.2	74
177	Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 126, 47-53.	0.6	74
178	Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. <i>Cancer Research</i> , 2002, 62, 932-40.	0.4	74
179	<i>TP53</i> Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2475-2485.	1.9	73
180	The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match. <i>Oncologist</i> , 2019, 24, 1-3.	1.9	73

#	ARTICLE	IF	CITATIONS
181	A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 25-34.	2.0	72
182	Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial. <i>Clinical Cancer Research</i> , 2013, 19, 5474-5484.	3.2	72
183	Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 1109-1124.	2.7	72
184	Overcoming Platinum Resistance through the Use of a Copper-Lowering Agent. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1221-1225.	1.9	70
185	Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic. <i>Clinical Cancer Research</i> , 2014, 20, 6336-6345.	3.2	70
186	Phase I trials as valid therapeutic options for patients with cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 773-778.	12.5	70
187	MHC-I genotype and tumor mutational burden predict response to immunotherapy. <i>Genome Medicine</i> , 2020, 12, 45.	3.6	70
188	Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 35-49.	0.6	68
189	Survival of patients in a Phase 1 clinic. <i>Cancer</i> , 2009, 115, 1091-1099.	2.0	68
190	Genomic Landscape of Malignant Mesotheliomas. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2498-2507.	1.9	68
191	Rearrangement in the Breakpoint Cluster Region and the Clinical Course in Philadelphia-Negative Chronic Myelogenous Leukemia. <i>Annals of Internal Medicine</i> , 1986, 105, 673.	2.0	67
192	Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2483-2494.	1.9	67
193	Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. , 2019, 7, 27.		66
194	Responses to Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Metaplastic Carcinoma of the Breast: Biologic Rationale and Implications for Stem-Cell Research in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, e572-e575.	0.8	65
195	The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. <i>Blood</i> , 2002, 100, 1215-9.	0.6	65
196	Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures. <i>PLoS ONE</i> , 2011, 6, e18424.	1.1	64
197	High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations. <i>OncImmunity</i> , 2017, 6, e1284719.	2.1	64
198	Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 130.	6.9	64

#	ARTICLE	IF	CITATIONS
199	Erythromelalgia: Review of clinical characteristics and pathophysiology. American Journal of Medicine, 1991, 91, 416-422.	0.6	63
200	Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clinical Cancer Research, 2015, 21, 4801-4810.	3.2	63
201	Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Investigational New Drugs, 2015, 33, 621-631.	1.2	63
202	Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. Molecular Cancer Therapeutics, 2016, 15, 533-547.	1.9	63
203	Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients. Molecular Cancer Therapeutics, 2019, 18, 448-458.	1.9	63
204	Targeting ARID1A mutations in cancer. Cancer Treatment Reviews, 2021, 100, 102287.	3.4	63
205	BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget, 2014, 5, 3607-3610.	0.8	63
206	Elevated Plasma Thrombopoietic Activity in Patients With Metastatic Cancer-Related Thrombocytosis. American Journal of Medicine, 1995, 98, 551-558.	0.6	61
207	Pilot Study of Low-Dose Interleukin-11 in Patients With Bone Marrow Failure. Journal of Clinical Oncology, 2001, 19, 4165-4172.	0.8	61
208	First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 1237-1246.	3.2	61
209	From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. Trends in Cancer, 2021, 7, 15-28.	3.8	61
210	Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience. Oncologist, 2011, 16, 1292-1298.	1.9	60
211	Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes. Cell Cycle, 2015, 14, 2219-2221.	1.3	60
212	APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. Oncoimmunology, 2019, 8, 1550341.	2.1	60
213	Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer. JAMA Oncology, 2019, 5, e183773.	3.4	60
214	Synthetic lethality-mediated precision oncology via the tumor transcriptome. Cell, 2021, 184, 2487-2502.e13.	13.5	60
215	Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types. Cell Cycle, 2015, 14, 2355-2361.	1.3	59
216	Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. British Journal of Cancer, 2017, 116, 432-440.	2.9	59

#	ARTICLE	IF	CITATIONS
217	Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2645-2655.	1.9	59
218	Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. <i>Clinical Cancer Research</i> , 2018, 24, 1881-1890.	3.2	59
219	Suberoylanilide hydroxamic acid (Zolanza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1596-1605.	1.9	58
220	Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors. <i>Oncology Reports</i> , 2009, 22, 1473-8.	1.2	58
221	Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra). <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1485-1488.	1.9	58
222	Reproducibility of Perfusion Parameters in Dynamic Contrast-Enhanced MRI of Lung and Liver Tumors: Effect on Estimates of Patient Sample Size in Clinical Trials and on Individual Patient Responses. <i>American Journal of Roentgenology</i> , 2010, 194, W134-W140.	1.0	58
223	Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?. <i>Oncologist</i> , 2020, 25, 94-98.	1.9	58
224	Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)., 2021, 9, e002990.		58
225	Tripe palms and cancer. <i>Clinics in Dermatology</i> , 1993, 11, 165-173.	0.8	57
226	Interferon therapy for orbital infiltration secondary to Erdheim-Chester disease. <i>American Journal of Ophthalmology</i> , 2001, 132, 945-947.	1.7	57
227	Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436). <i>Clinical Cancer Research</i> , 2014, 20, 4449-4458.	3.2	56
228	Challenging Standard-of-Care Paradigms in the Precision Oncology Era. <i>Trends in Cancer</i> , 2018, 4, 101-109.	3.8	56
229	Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center. <i>Journal of Oncology Practice</i> , 2015, 11, 442-449.	2.5	55
230	Reproducibility of CT Perfusion Parameters in Liver Tumors and Normal Liver. <i>Radiology</i> , 2011, 260, 762-770.	3.6	54
231	Precision medicine: lessons learned from the SHIVA trial. <i>Lancet Oncology</i> , The, 2015, 16, e579-e580.	5.1	54
232	Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. <i>Clinical Cancer Research</i> , 2019, 25, 6107-6118.	3.2	54
233	Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. <i>Clinical Cancer Research</i> , 2020, 26, 1247-1257.	3.2	54
234	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. <i>Oncotarget</i> , 2014, 5, 2349-2354.	0.8	54

#	ARTICLE	IF	CITATIONS
235	Prevalence of complementary medicine use in a phase 1 clinical trials program. <i>Cancer</i> , 2011, 117, 5142-5150.	2.0	53
236	Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2541-2546.	1.9	53
237	Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations. <i>Cancer Research</i> , 2014, 74, 7181-7184.	0.4	53
238	Molecular landscape of prostate cancer: Implications for current clinical trials. <i>Cancer Treatment Reviews</i> , 2015, 41, 761-766.	3.4	53
239	Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. <i>Oncotarget</i> , 2014, 5, 11168-11179.	0.8	53
240	Phase I Study of BMS-214662, a Farnesyl Transferase Inhibitor in Patients With Acute Leukemias and High-Risk Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2005, 23, 2805-2812.	0.8	52
241	Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. <i>European Journal of Cancer</i> , 2017, 83, 80-87.	1.3	52
242	<i>SMARCA4</i> : Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2341-2351.	1.9	52
243	Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1001-1006.	1.9	51
244	Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. <i>Investigational New Drugs</i> , 2013, 31, 1192-1200.	1.2	51
245	Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia. <i>Leukemia Research</i> , 1995, 19, 23-34.	0.4	50
246	Myelodysplastic syndrome overview. <i>Seminars in Hematology</i> , 2002, 39, 18-25.	1.8	50
247	Cutaneous castleman's disease responds to anti-interleukin-6 treatment. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2386-2390.	1.9	50
248	Multiple Squamous Cell Carcinomas of the Skin After Therapy With Sorafenib Combined With Tipifarnib. <i>Archives of Dermatology</i> , 2008, 144, 779-82.	1.7	50
249	Timing of palliative care referral and symptom burden in phase 1 cancer patients. <i>Cancer</i> , 2010, 116, 4402-4409.	2.0	50
250	Resistance to Mammalian Target of Rapamycin Inhibitor Therapy in Perivascular Epithelioid Cell Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, e415-e415.	0.8	50
251	High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2139-2145.	1.9	50
252	Dosing <i>de novo</i> combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers. <i>Oncotarget</i> , 2016, 7, 11310-11320.	0.8	50

#	ARTICLE	IF	CITATIONS
253	Targeting hypoxia-inducible factor-1 \pm (HIF-1 \pm) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab. <i>Oncotarget</i> , 2014, 5, 10280-10292.	0.8	49
254	A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30408-30419.	0.8	49
255	Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 263-275.	2.7	49
256	Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. <i>Communications Medicine</i> , 2022, 2, .	1.9	49
257	Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macroglobulinemia. <i>American Journal of Hematology</i> , 1988, 29, 1-4.	2.0	48
258	Abnormalities in thePRAD1 (CYCLIN D1 /BCL-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell lines. <i>Cancer</i> , 1995, 75, 584-590.	2.0	48
259	It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2549-2555.	1.9	48
260	A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. <i>Cancer</i> , 2021, 127, 3194-3201.	2.0	48
261	Leukemia Inhibitory Factor Binds to Human Breast Cancer Cells and Stimulates Their Proliferation. <i>Journal of Interferon and Cytokine Research</i> , 1995, 15, 905-913.	0.5	47
262	Uncommon tumors and exceptional therapies: paradox or paradigm?. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1175-1179.	1.9	47
263	A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temozolomide in Patients with Advanced Gynecologic and Breast Malignancies. <i>Clinical Cancer Research</i> , 2011, 17, 6840-6846.	3.2	47
264	Reproducibility of Perfusion Parameters Obtained From Perfusion CT in Lung Tumors. <i>American Journal of Roentgenology</i> , 2011, 197, 113-121.	1.0	47
265	Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1114-1122.	1.9	47
266	Interferon- γ therapy for chronic myelogenous leukemia. <i>American Journal of Medicine</i> , 1995, 99, 402-411.	0.6	46
267	Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs. <i>Clinical Cancer Research</i> , 2014, 20, 281-288.	3.2	46
268	Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 495-501.	1.1	46
269	Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival. <i>Annals of Surgical Oncology</i> , 2018, 25, 2400-2408.	0.7	46
270	Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2018, 23, 1300-1309.	1.9	46

#	ARTICLE	IF	CITATIONS
271	Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes. <i>Breast</i> , 2019, 44, 29-32.	0.9	46
272	Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. <i>Cancers</i> , 2019, 11, 11.	1.7	46
273	A Phase I Clinical Trial of Darinaparsin in Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 4769-4776.	3.2	45
274	The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. <i>Cell</i> , 2020, 180, 9-14.	13.5	45
275	Genomic landscape of salivary gland tumors. <i>Oncotarget</i> , 2015, 6, 25631-25645.	0.8	45
276	<i>BRAF</i> mutation testing with a rapid, fully integrated molecular diagnostics system. <i>Oncotarget</i> , 2015, 6, 26886-26894.	0.8	45
277	A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG) <i>TJ ETQq1.1 0.78434 rgBT</i>	1.1	44
278	Chronic myelogenous leukemia and sweet syndrome. <i>American Journal of Hematology</i> , 1989, 32, 134-137.	2.0	44
279	Phase I Clinical Trial of MPC-6827 (Azixa), a Microtubule Destabilizing Agent, in Patients with Advanced Cancer. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 3410-3419.	1.9	44
280	Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. <i>Cell Cycle</i> , 2015, 14, 1252-1259.	1.3	44
281	KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors. <i>PLoS ONE</i> , 2012, 7, e38033.	1.1	44
282	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. <i>Oncotarget</i> , 2016, 7, 67521-67531.	0.8	44
283	Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. <i>Genome Medicine</i> , 2021, 13, 155.	3.6	44
284	Significance and correlations of molecular analysis results in patients with philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. <i>American Journal of Medicine</i> , 1988, 85, 639-644.	0.6	43
285	Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors. <i>Journal of Cancer</i> , 2011, 2, 81-89.	1.2	43
286	Salivary Duct Carcinoma: Targeting the Phosphatidylinositol 3-Kinase Pathway by Blocking Mammalian Target of Rapamycin With Temsirolimus. <i>Journal of Clinical Oncology</i> , 2011, 29, e727-e730.	0.8	43
287	NF2/Merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations. <i>Oncotarget</i> , 2014, 5, 67-77.	0.8	43
288	Treatment of Patients With Advanced Neurofibromatosis Type 2 With Novel Molecularly Targeted Therapies: From Bench to Bedside. <i>Journal of Clinical Oncology</i> , 2012, 30, e64-e68.	0.8	42

#	ARTICLE	IF	CITATIONS
289	Safety, pharmacokinetics, and activity of EZN2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. <i>Cancer</i> , 2012, 118, 6144-6151.	2.0	42
290	Fool's gold, lost treasures, and the randomized clinical trial. <i>BMC Cancer</i> , 2013, 13, 193.	1.1	42
291	Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2857-2863.	1.9	42
292	Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2018, 24, 1785-1794.	3.2	42
293	MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis. <i>Journal of Hematology and Oncology</i> , 2018, 11, 76.	6.9	42
294	Challenges and perspective of drug repurposing strategies in early phase clinical trials. <i>Oncoscience</i> , 2015, 2, 576-580.	0.9	42
295	Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses. <i>Oncotarget</i> , 2013, 4, 890-898.	0.8	42
296	High Serum Interleukin-6 Levels Correlate with a Shorter Failure-Free Survival in Indolent Lymphoma. <i>Leukemia and Lymphoma</i> , 1998, 30, 563-571.	0.6	41
297	Combining Targeted Therapies: Practical Issues to Consider at the Bench and Bedside. <i>Oncologist</i> , 2010, 15, 37-50.	1.9	41
298	Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies. <i>Oncolmmunology</i> , 2018, 7, e1404217.	2.1	41
299	Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. <i>Oncolmmunology</i> , 2020, 9, 1708065.	2.1	41
300	Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. <i>International Journal of Cancer</i> , 2021, 148, 702-712.	2.3	41
301	Trichomegaly of the Eyelashes After Lung Cancer Treatment with the Epidermal Growth Factor Receptor Inhibitor Erlotinib. <i>Journal of Clinical Oncology</i> , 2008, 26, 3460-3462.	0.8	40
302	Salirasib in the treatment of pancreatic cancer. <i>Future Oncology</i> , 2010, 6, 885-891.	1.1	40
303	Genetics on a WHIM. <i>British Journal of Haematology</i> , 2014, 164, 15-23.	1.2	40
304	Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. <i>Oncotarget</i> , 2014, 5, 3029-3038.	0.8	40
305	Molecular characteristics of chronic myelogenous leukemia in blast crisis. <i>Cancer Genetics and Cytogenetics</i> , 1987, 27, 349-356.	1.0	39
306	Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. <i>American Journal of Medicine</i> , 1989, 86, 554-558.	0.6	39

#	ARTICLE	IF	CITATIONS
307	Farnesyltransferase inhibitors: where are we now?. Expert Opinion on Investigational Drugs, 2010, 19, 1569-1580.	1.9	39
308	Targeted therapy in rare cancers—adopting the orphans. Nature Reviews Clinical Oncology, 2012, 9, 631-642.	12.5	39
309	A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. Investigational New Drugs, 2013, 31, 967-973.	1.2	39
310	Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients. Oncologist, 2017, 22, 576-584.	1.9	39
311	Analysis of <i>MDM2</i> Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. JCO Precision Oncology, 2018, 2018, 1-14.	1.5	39
312	Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2020, 85, 673-683.	1.1	39
313	Genetic and Nongenetic Covariates of Pain Severity in Patients with Adenocarcinoma of the Pancreas: Assessing the Influence of Cytokine Genes. Journal of Pain and Symptom Management, 2009, 38, 894-902.	0.6	38
314	Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2010, 65, 235-241.	1.1	38
315	Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. Cancer Treatment Reviews, 2004, 30, 425-436.	3.4	37
316	Revisiting Epidermal Growth Factor Receptor (<i>EGFR</i>) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. JCO Precision Oncology, 2019, 3, 1-14.	1.5	37
317	Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening. Cancers, 2021, 13, 3600.	1.7	37
318	Epstein-Barr virus in patients with chronic lymphocytic leukemia: A pilot study. Leukemia and Lymphoma, 2006, 47, 827-836.	0.6	36
319	Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients. Clinical Cancer Research, 2017, 23, 1137-1148.	3.2	36
320	Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. Cancer, 2019, 125, 1185-1199.	2.0	36
321	Transcriptomics and solid tumors: The next frontier in precision cancer medicine. Seminars in Cancer Biology, 2022, 84, 50-59.	4.3	36
322	R1507, an Anti-Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antibody, and EWS/FLI-1 siRNA in Ewing's Sarcoma: Convergence at the IGF/IGFR/Akt Axis. PLoS ONE, 2011, 6, e26060.	1.1	35
323	Morphoproteomic Profiling of the Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Desmoplastic Small Round Cell Tumor (EWS/WT1), Ewing's Sarcoma (EWS/FLI1) and Wilms' Tumor (WT1). PLoS ONE, 2013, 8, e68985.	1.1	35
324	Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. Journal of Hematology and Oncology, 2019, 12, 145.	6.9	35

#	ARTICLE	IF	CITATIONS
325	Cancer of Unknown Primary in the Molecular Era. <i>Trends in Cancer</i> , 2021, 7, 465-477.	3.8	35
326	Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1987, 67, 55-59.	1.2	35
327	Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. <i>British Journal of Haematology</i> , 1997, 96, 328-332.	1.2	34
328	Phase I clinical trials for sarcomas: the cutting edge. <i>Current Opinion in Oncology</i> , 2011, 23, 352-360.	1.1	34
329	Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study. <i>Investigational New Drugs</i> , 2014, 32, 1181-1187.	1.2	34
330	Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. <i>Oncoscience</i> , 2016, 3, 164-172.	0.9	34
331	Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 265-272.	1.9	34
332	Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2017, 23, 4027-4034.	3.2	34
333	The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 297-305.	1.9	34
334	<i>GNAS</i> , <i>GNAQ</i> , and <i>GNA11</i> alterations in patients with diverse cancers. <i>Cancer</i> , 2018, 124, 4080-4089.	2.0	34
335	Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1001-1011.	1.9	34
336	Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. <i>Lancet Haematology</i> , 2020, 7, e209-e217.	2.2	34
337	Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. <i>Anticancer Research</i> , 2009, 29, 1895-9.	0.5	34
338	Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. <i>Cancer Discovery</i> , 2022, 12, 654-669.	7.7	34
339	OBSTRUCTIVE LUNG DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION. <i>Transplantation</i> , 1984, 37, 156-160.	0.5	33
340	Paraneoplastic erythromelalgia. <i>Clinics in Dermatology</i> , 1993, 11, 73-82.	0.8	33
341	Transformation of chronic lymphocytic leukemia to lymphoma of true histiocytic type. <i>Cancer</i> , 1995, 76, 609-617.	2.0	33
342	Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. <i>Seminars in Hematology</i> , 2002, 39, 20-24.	1.8	33

#	ARTICLE	IF	CITATIONS
343	Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non-Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2167-2175.	1.9	33
344	Interleukin-1 receptor antagonist levels predict favorable outcome after bevacizumab, a first-in-class true human interleukin-1 β antibody, in a phase III randomized study of advanced colorectal cancer. <i>Oncology</i> , 2019, 8, 1551651.	2.1	33
345	Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy. <i>Molecular Oncology</i> , 2020, 14, 1680-1694.	2.1	33
346	The paradox of cancer genes in non-malignant conditions: implications for precision medicine. <i>Genome Medicine</i> , 2020, 12, 16.	3.6	33
347	Moving Beyond 3+3: The Future of Clinical Trial Design. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e133-e144.	1.8	33
348	Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer. <i>Oncotarget</i> , 2013, 4, 118-127.	0.8	33
349	Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics. <i>Oncotarget</i> , 2016, 7, 23454-23467.	0.8	33
350	Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients. <i>British Journal of Haematology</i> , 1991, 78, 352-358.	1.2	32
351	Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The M. D. Anderson Cancer Center Experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4423-4432.	1.8	32
352	A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. <i>Investigational New Drugs</i> , 2010, 28, 634-640.	1.2	32
353	Transformation of Human Mesenchymal Cells and Skin Fibroblasts into Hematopoietic Cells. <i>PLoS ONE</i> , 2011, 6, e21250.	1.1	32
354	Merkel Cell Polyomavirus and HPV-17 Associated With Cutaneous Squamous Cell Carcinoma Arising in a Patient With Melanoma Treated With the BRAF Inhibitor Dabrafenib. <i>JAMA Dermatology</i> , 2013, 149, 322.	2.0	32
355	Novel Secondary Somatic Mutations in Ewing's Sarcoma and Desmoplastic Small Round Cell Tumors. <i>PLoS ONE</i> , 2014, 9, e93676.	1.1	32
356	Universal Genomic Testing Needed to Win the War Against Cancer. <i>JAMA Oncology</i> , 2016, 2, 719.	3.4	32
357	Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues. <i>Cancer Biology and Therapy</i> , 2020, 21, 95-100.	1.5	32
358	The pathogenesis of Sweet's syndrome. <i>Journal of the American Academy of Dermatology</i> , 1991, 25, 734.	0.6	31
359	Polycystic ovary syndrome in men: Stein-Leventhal syndrome revisited. <i>Medical Hypotheses</i> , 2007, 68, 480-483.	0.8	31
360	Cetuximab-Associated Elongation of the Eyelashes. <i>American Journal of Clinical Dermatology</i> , 2011, 12, 63-67.	3.3	31

#	ARTICLE	IF	CITATIONS
361	Combining Curcumin (Diferuloylmethane) and Heat Shock Protein Inhibition for Neurofibromatosis 2 Treatment: Analysis of Response and Resistance Pathways. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2094-2103.	1.9	31
362	Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3175-3184.	1.9	31
363	Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 467-473.	1.1	31
364	Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. <i>Investigational New Drugs</i> , 2014, 32, 465-472.	1.2	31
365	Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1682-1690.	1.9	31
366	Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. <i>International Journal of Cancer</i> , 2016, 139, 2135-2141.	2.3	31
367	Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1663.	1.8	31
368	Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach. <i>Oncologist</i> , 2018, 23, 171-178.	1.9	31
369	Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing. <i>Genome Medicine</i> , 2020, 12, 61.	3.6	31
370	Androgen receptors beyond prostate cancer: an old marker as a new target. <i>Oncotarget</i> , 2015, 6, 592-603.	0.8	31
371	Effect of differentiation-inducing agents on oncogene expression in a chronic myelogenous leukemia cell line. <i>Cancer</i> , 1988, 62, 1171-1178.	2.0	30
372	The Role of Investigational Therapy in Management of Patients With Advanced Metastatic Malignancy. <i>Journal of Clinical Oncology</i> , 2009, 27, 304-306.	0.8	30
373	Biomarker-Directed Therapy of Squamous Carcinomas of the Head and Neck: Targeting PI3K/PTEN/mTOR Pathway. <i>Journal of Clinical Oncology</i> , 2013, 31, e137-e140.	0.8	30
374	SU2C Phase 1b Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	30
375	Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. <i>JCO Precision Oncology</i> , 2019, 3, 1-16.	1.5	30
376	Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. <i>Cancer Biology and Therapy</i> , 2019, 20, 219-226.	1.5	30
377	Cyclin alterations in diverse cancers: outcome and co-amplification network. <i>Oncotarget</i> , 2015, 6, 3033-3042.	0.8	30
378	Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 200-204.	0.6	29

#	ARTICLE	IF	CITATIONS
379	Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2991-3000.	1.9	29
380	Evaluation of the Clinical Relevance of Body Composition Parameters in Patients With Cancer Metastatic to the Liver Treated With Hepatic Arterial Infusion Chemotherapy. <i>Nutrition and Cancer</i> , 2012, 64, 206-217.	0.9	29
381	Non-“Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment. <i>Journal of Thoracic Oncology</i> , 2013, 8, e19-e20.	0.5	29
382	An appraisal of drug development timelines in the Era of precision oncology. <i>Oncotarget</i> , 2016, 7, 53037-53046.	0.8	29
383	Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. <i>Oncolimmunology</i> , 2017, 6, e1338997.	2.1	29
384	SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	29
385	Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 6029-6039.	0.8	29
386	Trisomy 12 correlates with elevated expression of p21ras in a human adenosquamous carcinoma of the lung. <i>Cancer Genetics and Cytogenetics</i> , 1986, 23, 183-188.	1.0	28
387	Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver. <i>Cancer</i> , 2007, 109, 2190-2196.	2.0	28
388	A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. <i>European Journal of Cancer</i> , 2017, 83, 229-236.	1.3	28
389	Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. <i>Molecular Oncology</i> , 2021, 15, 67-79.	2.1	28
390	Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1634-1647.	3.0	28
391	Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. <i>Oncotarget</i> , 2014, 5, 1846-1855.	0.8	28
392	Very low doses of GM-CSF administered alone or with erythropoietin in a plastic anemia. <i>American Journal of Medicine</i> , 1992, 93, 41-48.	0.6	27
393	Activity of interferon- γ and isotretinoin in patients with advanced, refractory lymphoid malignancies. <i>Cancer</i> , 2004, 100, 574-580.	2.0	27
394	Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. <i>Cancer</i> , 2014, 120, 2164-2173.	2.0	27
395	Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. <i>British Journal of Cancer</i> , 2018, 118, 1042-1050.	2.9	27
396	Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics. <i>Clinical Cancer Research</i> , 2021, 27, 2792-2797.	3.2	27

#	ARTICLE	IF	CITATIONS
397	New drug approvals in oncology. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 140-146.	12.5	27
398	<i>c-MET</i> aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. <i>Oncotarget</i> , 2014, 5, 1837-1845.	0.8	27
399	A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R): Implications for inhibition of the IGF-1R signal. <i>Oncotarget</i> , 2013, 4, 463-473.	0.8	27
400	Thrombopoietic Factors in Chronic Bone Marrow Failure States: The Platelet Problem Revisited: Table 1. <i>Clinical Cancer Research</i> , 2005, 11, 1361-1367.	3.2	26
401	Turmeric and Green Tea: A Recipe for the Treatment of B-Chronic Lymphocytic Leukemia: Fig. 1.. <i>Clinical Cancer Research</i> , 2009, 15, 1123-1125.	3.2	26
402	A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. <i>Cancer</i> , 2010, 116, 4086-4094.	2.0	26
403	A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 918-926.	1.2	26
404	The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases. <i>Clinical Cancer Research</i> , 2015, 21, 4561-4568.	3.2	26
405	Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. <i>Supportive Care in Cancer</i> , 2015, 23, 2649-2654.	1.0	26
406	Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 869-874.	1.1	26
407	Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1149-1157.	1.9	26
408	Selpercatinib Aimed at <i>RET</i> -Altered Cancers. <i>New England Journal of Medicine</i> , 2020, 383, 868-869.	13.9	26
409	Transcriptomic silencing as a potential mechanism of treatment resistance. <i>JCI Insight</i> , 2020, 5, .	2.3	26
410	A framework for genomic biomarker actionability and its use in clinical decision making. <i>Oncoscience</i> , 2014, 1, 614-623.	0.9	26
411	Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia. <i>Cancer</i> , 1992, 69, 410-412.	2.0	25
412	Advance Care Planning in Patients With Cancer Referred to a Phase I Clinical Trials Program: The MD Anderson Cancer Center Experience. <i>Journal of Clinical Oncology</i> , 2012, 30, 2891-2896.	0.8	25
413	A pilot study of temsirolimus and body composition. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2013, 4, 259-265.	2.9	25
414	A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. <i>Investigational New Drugs</i> , 2015, 33, 177-186.	1.2	25

#	ARTICLE	IF	CITATIONS
415	Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. <i>BMC Cancer</i> , 2015, 15, 61.	1.1	25
416	Molecular Tumor Boards: Realizing Precision Oncology Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 206-209.	2.3	25
417	Identification of targets for prostate cancer immunotherapy. <i>Prostate</i> , 2019, 79, 498-505.	1.2	25
418	MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. <i>Oncoscience</i> , 2013, 1, 5-13.	0.9	25
419	The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines. <i>Biochemical Pharmacology</i> , 2008, 75, 836-846.	2.0	24
420	Phase I Clinical Trial Outcomes in 93 Patients with Brain Metastases: The MD Anderson Cancer Center Experience. <i>Clinical Cancer Research</i> , 2011, 17, 4110-4118.	3.2	24
421	Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1089-1096.	1.1	24
422	Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management. <i>Seminars in Oncology</i> , 2015, 42, 863-875.	0.8	24
423	STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications. <i>European Journal of Cancer</i> , 2021, 148, 215-229.	1.3	24
424	Germline <i>PTPRD</i> Mutations in Ewing Sarcoma: Biologic and Clinical Implications. <i>Oncotarget</i> , 2013, 4, 884-889.	0.8	24
425	A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. <i>Oncotarget</i> , 2015, 6, 18693-18706.	0.8	24
426	Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2006, 47, 2049-2054.	0.6	23
427	NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1337-1346.	2.3	23
428	What have we learned from SHIVA?. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 719-720.	12.5	23
429	Debunking the Delusion That Precision Oncology Is an Illusion. <i>Oncologist</i> , 2017, 22, 881-882.	1.9	23
430	The importance of greater speed in drug development for advanced malignancies. <i>Cancer Medicine</i> , 2018, 7, 1824-1836.	1.3	23
431	Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. <i>Cancer Immunology Research</i> , 2019, 7, 866-873.	1.6	23
432	Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. <i>Oncotarget</i> , 2016, 7, 23227-23238.	0.8	23

#	ARTICLE	IF	CITATIONS
433	Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 237-242.	1.1	22
434	Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome. <i>Clinical Cancer Research</i> , 2008, 14, 509-514.	3.2	22
435	Chemotherapy Resistance and Retreatment: A Dogma Revisited. <i>Clinical Colorectal Cancer</i> , 2010, 9, E1-E4.	1.0	22
436	Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 247-253.	1.1	22
437	Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin-Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1300-1307.	1.9	22
438	Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability. <i>Cancer Research</i> , 2017, 77, 6313-6320.	0.4	22
439	Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 616-626.	1.2	22
440	Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 863-866.	2.3	22
441	Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1852-1862.	1.9	22
442	Circulating Tumor Cells: From the Laboratory to the Cancer Clinic. <i>Cancers</i> , 2020, 12, 2361.	1.7	22
443	Dual EGFR Inhibition in combination with anti-VEGF treatment in colorectal cancer. <i>Oncoscience</i> , 2014, 1, 540-549.	0.9	22
444	A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 14139-14152.	0.8	22
445	The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. <i>Oncotarget</i> , 2016, 7, 20293-20304.	0.8	22
446	Ewing's sarcoma: overcoming the therapeutic plateau. <i>Discovery Medicine</i> , 2012, 13, 405-15.	0.5	22
447	Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. <i>Anticancer Research</i> , 2014, 34, 1939-45.	0.5	22
448	Extracutaneous Manifestations of Sweet's Syndrome: Steroid-Responsive Culture-Negative Pulmonary Lesions. <i>The American Review of Respiratory Disease</i> , 1992, 146, 269-269.	2.9	21
449	Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses. <i>Cancer</i> , 2003, 98, 2410-2419.	2.0	21
450	Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non-Small Cell Lung Cancer Published between 2000 and 2009. <i>Clinical Cancer Research</i> , 2012, 18, 6356-6363.	3.2	21

#	ARTICLE	IF	CITATIONS
451	Eyelash trichomegaly: review of congenital, acquired, and drug-associated etiologies for elongation of the eyelashes. <i>International Journal of Dermatology</i> , 2012, 51, 631-646.	0.5	21
452	A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 167-177.e2.	0.9	21
453	Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients. <i>Cancer</i> , 2018, 124, 1288-1296.	2.0	21
454	Historical communication: Philadelphia-positive chronic myelogenous leukemia followed for 27 years. <i>Cancer Genetics and Cytogenetics</i> , 1988, 34, 57-61.	1.0	20
455	Phase I Study of a Combination of Recombinant Tumor Necrosis Factor- α and Recombinant Interferon- γ in Cancer Patients. <i>Journal of Interferon Research</i> , 1989, 9, 435-444.	1.2	20
456	Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit. <i>Oncologist</i> , 2013, 18, 1315-1320.	1.9	20
457	Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 4824-4831.	3.2	20
458	Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 427-432.	1.1	20
459	Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. <i>International Journal of Cancer</i> , 2020, 146, 3087-3097.	2.3	20
460	IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. <i>Cancers</i> , 2020, 12, 1768.	1.7	20
461	Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens. <i>JCI Insight</i> , 2021, 6, .	2.3	20
462	Evaluation of liposomal curcumin cytochrome p450 metabolism. <i>Anticancer Research</i> , 2010, 30, 811-4.	0.5	20
463	Malignancy-associated tripe palms. <i>Journal of the American Academy of Dermatology</i> , 1992, 27, 271-272.	0.6	19
464	The changing face of Phase 1 cancer clinical trials. <i>Cancer</i> , 2009, 115, 1592-1597.	2.0	19
465	Binding partners for curcumin in human schwannoma cells: Biologic Implications. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 932-939.	1.4	19
466	Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. <i>Immunotherapy</i> , 2016, 8, 17-26.	1.0	19
467	Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting. <i>International Journal of Cancer</i> , 2020, 146, 566-576.	2.3	19
468	High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment. <i>International Journal of Cancer</i> , 2021, 148, 2839-2847.	2.3	19

#	ARTICLE	IF	CITATIONS
469	Missing the target in cancer therapy. <i>Nature Cancer</i> , 2021, 2, 369-371.	5.7	19
470	Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns. <i>Oncologist</i> , 2021, 26, 787-796.	1.9	19
471	Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response. <i>Clinical Cancer Research</i> , 2022, 28, 187-200.	3.2	19
472	Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. <i>Oncotarget</i> , 2015, 6, 43127-43134.	0.8	19
473	Farnesyltransferase inhibitors: Novel compounds in development for the treatment of myeloid malignancies. <i>Seminars in Hematology</i> , 2002, 39, 26-30.	1.8	18
474	Project Zero Delay: A Process for Accelerating the Activation of Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 4433-4440.	0.8	18
475	Epidermal growth factor receptor mutation and diverse tumors: Case report and concise literature review. <i>Molecular Oncology</i> , 2010, 4, 306-308.	2.1	18
476	A Comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors. <i>Investigational New Drugs</i> , 2012, 30, 327-334.	1.2	18
477	NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1629-1649.	2.3	18
478	MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e19-e26.	0.9	18
479	Next-Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients With Lymphoid Malignancies. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	1.5	18
480	Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response. <i>Frontiers in Oncology</i> , 2018, 8, 435.	1.3	18
481	Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions. <i>Oncologist</i> , 2021, 26, e78-e89.	1.9	18
482	Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. <i>Oncotarget</i> , 2017, 8, 67782-67789.	0.8	18
483	Click chemistry, 3D-printing, and omics: the future of drug development. <i>Oncotarget</i> , 2016, 7, 2155-2158.	0.8	18
484	Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis. <i>Stem Cells</i> , 1993, 11, 112-119.	1.4	17
485	Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 1087-1093.	1.1	17
486	The inverted pyramid of biomarker-driven trials. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 562-566.	12.5	17

#	ARTICLE	IF	CITATIONS
487	VEGF and dual-EGFR inhibition in colorectal cancer. <i>Cell Cycle</i> , 2015, 14, 1129-1130.	1.3	17
488	The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers. <i>Seminars in Oncology</i> , 2015, 42, 731-739.	0.8	17
489	A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 5475-5484.	3.2	17
490	Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease. <i>Oncologist</i> , 2020, 25, e386-e390.	1.9	17
491	A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 309-317.e3.	0.2	17
492	Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. <i>Oncolimmunology</i> , 2020, 9, 1710052.	2.1	17
493	Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. <i>Oncotarget</i> , 2016, 7, 64421-64430.	0.8	17
494	Treatment of cyclic neutropenia with very low doses of GM-CSF. <i>American Journal of Medicine</i> , 1991, 91, 317-318.	0.6	16
495	Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon γ : involvement of tumor necrosis factor as ligand for the CD95 receptor. <i>Blood</i> , 2001, 97, 2791-2797.	0.6	16
496	Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms. <i>JCO Precision Oncology</i> , 2020, 4, 972-987.	1.5	16
497	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 5579-5587.	3.2	16
498	Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population. <i>Oncotarget</i> , 2013, 4, 772-784.	0.8	16
499	Role of Interleukin-1 Inhibitory Molecules in Therapy of Acute and Chronic Myelogenous Leukemia. <i>Leukemia and Lymphoma</i> , 1993, 10, 407-418.	0.6	15
500	Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administration-Approved Treatment. <i>Clinical Cancer Research</i> , 2010, 16, 4031-4037.	3.2	15
501	Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. <i>Oncotarget</i> , 2015, 6, 32602-32609.	0.8	15
502	Apoptosis in Chronic Myelogenous Leukemia: Studies of Stage-Specific Differences. <i>Leukemia and Lymphoma</i> , 1997, 25, 121-133.	0.6	14
503	Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: The M. D. Anderson Cancer Center experience. <i>American Journal of Hematology</i> , 2009, 84, 408-413.	2.0	14
504	Phase I clinical trials in 85 patients with gynecologic cancer: The M. D. Anderson Cancer Center experience. <i>Gynecologic Oncology</i> , 2010, 117, 467-472.	0.6	14

#	ARTICLE	IF	CITATIONS
505	Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. <i>Investigational New Drugs</i> , 2014, 32, 279-286.	1.2	14
506	U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009. <i>Clinical Cancer Research</i> , 2014, 20, 3364-3370.	3.2	14
507	A cancer trial scandal and its regulatory backlash. <i>Nature Biotechnology</i> , 2014, 32, 27-31.	9.4	14
508	Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 699-706.	3.4	14
509	Cancer research in the United States: A critical review of current status and proposal for alternative models. <i>Cancer</i> , 2018, 124, 2881-2889.	2.0	14
510	Targeting fusions for improved outcomes in oncology treatment. <i>Cancer</i> , 2020, 126, 1315-1321.	2.0	14
511	Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. <i>International Journal of Cancer</i> , 2020, 146, 3450-3460.	2.3	14
512	Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , 2020, 27, 3259-3267.	0.7	14
513	Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1312.	1.3	14
514	Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden. <i>Molecular Oncology</i> , 2020, 14, 1242-1251.	2.1	14
515	Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers. <i>JCO Precision Oncology</i> , 2020, 4, 192-201.	1.5	14
516	A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. <i>Oncotarget</i> , 2014, 5, 11154-11167.	0.8	14
517	Thrombopoietin Stimulates Myelodysplastic Syndrome Granulocyte-Macrophage and Erythroid Progenitor Proliferation. <i>Leukemia and Lymphoma</i> , 1998, 30, 279-292.	0.6	13
518	Therapy of T Cell Lymphomas with Pentostatin. <i>Annals of the New York Academy of Sciences</i> , 2001, 941, 200-205.	1.8	13
519	Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 389-397.	1.1	13
520	Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. <i>Clinical Epigenetics</i> , 2015, 7, 29.	1.8	13
521	Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus. <i>Cell</i> , 2017, 171, 982-986.	13.5	13
522	Snapshot: Trial Types in Precision Medicine. <i>Cell</i> , 2020, 181, 208-208.e1.	13.5	13

#	ARTICLE	IF	CITATIONS
523	Molecular Profiling and the Reclassification of Cancer: Divide and Conquer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 127-134.	1.8	13
524	Epstein-Barr Virus in Patients with Chronic Lymphocytic Leukemia.. Blood, 2005, 106, 2113-2113.	0.6	13
525	Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. Discovery Medicine, 2015, 19, 109-16.	0.5	13
526	What is the contribution of molecular studies to the diagnosis of BCR-ABL-positive disease in adult acute leukemia?. American Journal of Medicine, 1994, 96, 133-138.	0.6	12
527	Purine Analogues in Advanced T-Cell Lymphoid Malignancies. Seminars in Hematology, 2006, 43, S27-S34.	1.8	12
528	Incidence of Mucositis in Patients Treated With Temsirolimus-Based Regimens and Correlation to Treatment Response. Oncologist, 2014, 19, 426-428.	1.9	12
529	Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Investigational New Drugs, 2015, 33, 700-709.	1.2	12
530	The right to try is embodied in the right to die. Nature Reviews Clinical Oncology, 2016, 13, 399-400.	12.5	12
531	New therapeutic approaches to overcoming resistant EGFR exon 20 alterations. Critical Reviews in Oncology/Hematology, 2020, 151, 102990.	2.0	12
532	Minimal Residual Disease in Hematologic Disorders. Archives of Pathology and Laboratory Medicine, 1999, 123, 1030-1034.	1.2	12
533	Phase II evaluation of PALA in patients with refractory metastatic sarcomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 1984, 7, 305-308.	0.6	11
534	Effect of Dual Vascular Input Functions on CT Perfusion Parameter Values and Reproducibility in Liver Tumors and Normal Liver. Journal of Computer Assisted Tomography, 2012, 36, 388-393.	0.5	11
535	A Tale of Two Histiocytic Disorders. Oncologist, 2013, 18, 2-4.	1.9	11
536	Compliance in Early-Phase Cancer Clinical Trials Research. Oncologist, 2013, 18, 308-313.	1.9	11
537	The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. Oncologist, 2015, 20, 737-741.	1.9	11
538	Multiple gene aberrations and breast cancer: lessons from super-responders. BMC Cancer, 2015, 15, 442.	1.1	11
539	Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. Clinical Cancer Research, 2017, 23, 1407-1413.	3.2	11
540	Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Experimental Hematology and Oncology, 2020, 9, 7.	2.0	11

#	ARTICLE	IF	CITATIONS
541	High-Risk Myelodysplastic Syndrome (MDS): First Results of International Phase 2 Study with Oral Farnesyltransferase Inhibitor R115777 (ZARNESTRATM).. Blood, 2004, 104, 68-68.	0.6	11
542	Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget, 2014, 5, 3871-3879.	0.8	11
543	Assessing CAR T-cell therapy response using genome-wide sequencing of cell-free DNA in patients with B-cell lymphomas. Transplantation and Cellular Therapy, 2021, 28, 30.e1-30.e1.	0.6	11
544	Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair. Clinical Cancer Research, 2003, 9, 3722-30.	3.2	11
545	Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting. Oncoimmunology, 2022, 11, 2052410.	2.1	11
546	Clinical Outcomes of Patients With Breast Cancer in a Phase I Clinic: The M. D. Anderson Cancer Center Experience. Clinical Breast Cancer, 2010, 10, 46-51.	1.1	10
547	Posterior Reversible Encephalopathy Syndrome: More Than Meets the Eye. Journal of Clinical Oncology, 2013, 31, e360-e363.	0.8	10
548	Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic. Clinical Cancer Research, 2014, 20, 5956-5963.	3.2	10
549	Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. Drugs in R and D, 2016, 16, 45-52.	1.1	10
550	JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease. JAMA Dermatology, 2017, 153, 449.	2.0	10
551	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF μ mutated melanoma and other advanced malignancies. Cancer, 2019, 125, 463-472.	2.0	10
552	Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA μ TP53 μ Mutations μ A Perspective from a Real-World Precision Medicine Cohort. Molecular Cancer Therapeutics, 2020, 19, 2612-2620.	1.9	10
553	Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients. Oncoimmunology, 2020, 9, 1773200.	2.1	10
554	2-Chlorodeoxyadenosine-Associated Transient Acantholytic Dermatitis in Hairy Cell Leukemia Patients. American Journal of Dermatopathology, 1999, 21, 106-107.	0.3	10
555	Personalized, molecularly matched combination therapies for treatment-na.. Journal of Clinical Oncology, 2017, 35, 2512-2512.	0.8	10
556	Actionability and precision oncology. Oncoscience, 2015, 2, 779-780.	0.9	10
557	The "shield sign" in two men with metastatic salivary duct carcinoma to the skin: cutaneous metastases presenting as carcinoma hemorrhagictoides. Journal of Clinical and Aesthetic Dermatology, 2012, 5, 27-36.	0.1	10
558	Classification and Diagnosis of Erythromelalgia. International Journal of Dermatology, 1995, 34, 146-147.	0.5	9

#	ARTICLE	IF	CITATIONS
559	7 The M.D. Anderson Cancer Center experience with interferon- α therapy in chronic myelogenous leukaemia. <i>Best Practice and Research: Clinical Haematology</i> , 1997, 10, 291-305.	1.1	9
560	Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 382-386.	0.6	9
561	Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. <i>Clinical Epigenetics</i> , 2014, 6, 2.	1.8	9
562	Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. <i>Clinical Epigenetics</i> , 2014, 6, 13.	1.8	9
563	Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications. <i>Dermatology and Therapy</i> , 2015, 5, 129-143.	1.4	9
564	An avatar for precision cancer therapy. <i>Nature Biotechnology</i> , 2018, 36, 1053-1055.	9.4	9
565	Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials. <i>International Journal of Cancer</i> , 2020, 147, 2537-2549.	2.3	9
566	<i>KRAS</i> -Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery. <i>Oncologist</i> , 2021, 26, e530-e536.	1.9	9
567	Interleukin-3. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1991, 14, S45-50.	0.6	9
568	Relationship between tumor mutational burden and maximum standardized uptake value in 2-[¹⁸ F]FDG PET (positron emission tomography) scan in cancer patients. <i>EJNMMI Research</i> , 2020, 10, 150.	1.1	9
569	Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. <i>Oncotarget</i> , 2015, 6, 28453-28462.	0.8	9
570	Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. <i>Hepato-Gastroenterology</i> , 2013, 60, 1611-23.	0.5	9
571	Herpes simplex virus infections and Cimetidine therapy. <i>Journal of the American Academy of Dermatology</i> , 1988, 19, 762-763.	0.6	8
572	RAS inhibitors in hematologic cancers: biologic considerations and clinical applications. , 1999, 17, 137-143.		8
573	Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies. <i>Seminars in Hematology</i> , 2002, 39, 36-38.	1.8	8
574	Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2010, 9, 311-314.	1.0	8
575	Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Treated in a Phase I Clinic. <i>Oncologist</i> , 2011, 16, 327-335.	1.9	8
576	Phase 1 clinical trials in 83 patients with pancreatic cancer. <i>Cancer</i> , 2011, 117, 77-85.	2.0	8

#	ARTICLE	IF	CITATIONS
577	Factors related to biopsy willingness in patients with advanced cancer in a phase I clinic for molecularly targeted therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 963-970.	1.2	8
578	Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 154-159.	1.2	8
579	Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 215-224.	1.2	8
580	Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer. <i>Cell Cycle</i> , 2015, 14, 1730-1737.	1.3	8
581	Bringing Blood-Based Molecular Testing to the Clinic. <i>Clinical Cancer Research</i> , 2016, 22, 5400-5402.	3.2	8
582	Polycystic ovary syndrome in men. <i>Medical Hypotheses</i> , 2017, 103, 64.	0.8	8
583	Genomics of Immunotherapy-Associated Hyperprogressors' Response. <i>Clinical Cancer Research</i> , 2017, 23, 6376-6376.	3.2	8
584	Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunodeficiency virus and cancer. , 2019, 7, 130.		8
585	Tumor mutational burden is not predictive of cytotoxic chemotherapy response. <i>Oncotarget</i> , 2020, 9, 17819-17827.	2.1	8
586	Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2015, 53, 563-572.	0.3	8
587	Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. <i>Anticancer Research</i> , 2014, 34, 2349-55.	0.5	8
588	Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. <i>Discovery Medicine</i> , 2014, 18, 331-9.	0.5	8
589	Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience. <i>Molecular Oncology</i> , 2022, 16, 2575-2584.	2.1	8
590	Therapy of Chronic Myelogenous Leukemia with Interferon. <i>Cancer Investigation</i> , 1989, 7, 83-91.	0.6	7
591	Chronic myelogenous leukemia in chronic phase. <i>Current Treatment Options in Oncology</i> , 2001, 2, 245-252.	1.3	7
592	Molecular imaging of Bcr-Abl phosphokinase in a xenograft model. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 703-710.	1.9	7
593	Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients with Advanced Malignancies: A Phase I Clinical Trial. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 209-217.	1.9	7
594	Cutaneous Castleman disease. <i>British Journal of Haematology</i> , 2012, 157, 652-652.	1.2	7

#	ARTICLE	IF	CITATIONS
595	Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. <i>Investigational New Drugs</i> , 2015, 33, 911-920.	1.2	7
596	Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. <i>International Journal of Cancer</i> , 2017, 140, 208-215.	2.3	7
597	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. <i>British Journal of Cancer</i> , 2018, 118, 1419-1424.	2.9	7
598	Schnitzler syndrome associated with MYD88 L265P mutation. <i>JAAD Case Reports</i> , 2019, 5, 312-316.	0.4	7
599	Repurposing Interleukin-6 Inhibitors to Combat COVID-19. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 52-55.	0.6	7
600	Basal cell carcinoma: Management of advanced or metastatic cancer with checkpoint inhibitors and concurrent paradoxical development of new superficial tumors. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, e253-e254.	0.6	7
601	The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments. <i>Cancers</i> , 2020, 12, 166.	1.7	7
602	Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The university of Texas MD Anderson cancer center experience. <i>Oncoscience</i> , 2014, 1, 522-530.	0.9	7
603	Are Cancer Patients at Higher Risk of Death with COVID-19? Are Cancer Patients at Higher Risk of Death with Coronavirus Disease-19?. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 49-51.	0.6	7
604	Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine. <i>JCO Precision Oncology</i> , 2022, 6, e2000508.	1.5	7
605	A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2022, 11, 2790-2800.	1.3	7
606	Refractory Hodgkin lymphoma responds to pentostatin (2-deoxycoformycin). <i>Leukemia and Lymphoma</i> , 2006, 47, 373-375.	0.6	6
607	Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: The MD Anderson Cancer Center Experience. <i>Clinical Colorectal Cancer</i> , 2012, 11, 297-303.	1.0	6
608	Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. <i>Targeted Oncology</i> , 2013, 8, 183-188.	1.7	6
609	Effect of duration of scan acquisition on CT perfusion parameter values in primary and metastatic tumors in the lung. <i>European Journal of Radiology</i> , 2013, 82, 1811-1818.	1.2	6
610	Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies. <i>Cell Cycle</i> , 2015, 14, 3434-3440.	1.3	6
611	Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience. <i>Oncologist</i> , 2020, 25, e1803-e1806.	1.9	6
612	Balancing clinical evidence in the context of a pandemic. <i>Nature Biotechnology</i> , 2021, 39, 270-274.	9.4	6

#	ARTICLE	IF	CITATIONS
613	<i>BRAF</i> V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1072-1079.	1.9	6
614	CNTO 328, a Monoclonal Antibody to Interleukin-6, Is Active as a Single Agent in Castleman's Disease: Preliminary Results of a Phase I Study. <i>Blood</i> , 2008, 112, 1008-1008.	0.6	6
615	Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF, or hedgehog alterations: Interim data from MyPathway. <i>Journal of Clinical Oncology</i> , 2017, 35, 9073-9073.	0.8	6
616	Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. <i>Oncotarget</i> , 2014, 5, 8937-8946.	0.8	6
617	TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET). <i>Oncotarget</i> , 2018, 9, 14306-14310.	0.8	6
618	Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary. <i>JCO Precision Oncology</i> , 2021, 5, 1687-1698.	1.5	6
619	Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. <i>Discovery Medicine</i> , 2014, 18, 323-30.	0.5	6
620	Analysis of <i>CDK12</i> alterations in a pan-cancer database. <i>Cancer Medicine</i> , 2022, 11, 753-763.	1.3	6
621	The Modulatory Hematopoietic Activities of Leukemia Inhibitory Factor. <i>Leukemia and Lymphoma</i> , 1992, 8, 1-7.	0.6	5
622	Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1507-1516.	1.1	5
623	Dodging a dogma: is treating beyond progression beneficial?. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1385-1386.	1.1	5
624	Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1097-1102.	1.1	5
625	<i>BRAF</i> mutation as a novel driver of eosinophilic cystitis. <i>Cancer Biology and Therapy</i> , 2017, 18, 655-659.	1.5	5
626	Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics. <i>Oncologist</i> , 2021, 26, e715-e718.	1.9	5
627	Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. <i>Npj Precision Oncology</i> , 2021, 5, 33.	2.3	5
628	Cutaneous T Cell Lymphoma: Responses in Phase I Trial of Combination Therapy with Liposomal Doxorubicin, Bortezomib, and Gemcitabine. <i>Blood</i> , 2006, 108, 2466-2466.	0.6	5
629	Population Pharmacokinetic and Pharmacodynamic Modeling of an Anti-Interleukin-6 Chimeric Monoclonal Antibody, Siltuximab (CNTO 328), in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease. <i>Blood</i> , 2012, 120, 1365-1365.	0.6	5
630	Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: Interim data from MyPathway. <i>Journal of Clinical Oncology</i> , 2017, 35, 6086-6086.	0.8	5

#	ARTICLE	IF	CITATIONS
631	The Impact of COVID-19 on Cancer Clinical Trials Conducted by NCI-Designated Comprehensive Cancer Centers. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 56-63.	0.6	5
632	Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers. <i>Genome Medicine</i> , 2021, 13, 159.	3.6	5
633	Farnesyltransferase inhibitors. <i>Clinical Advances in Hematology and Oncology</i> , 2005, 3, 161-2.	0.3	5
634	Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy. <i>Frontiers in Oncology</i> , 2022, 12, 802579.	1.3	5
635	Association of <i>CD274</i> (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2022, 27, 732-739.	1.9	5
636	Alpha Interferon Dose-Dependent Suppression of Secondary Clones in a Patient with Philadelphia-Positive Chronic Myelogenous Leukemia. <i>Acta Haematologica</i> , 1990, 83, 149-151.	0.7	4
637	Interleukin-1 increases expression of the LYT-10 (NF κ B2) proto-oncogene/transcription factor in renal cell carcinoma lines. <i>Translational Research</i> , 1998, 131, 261-268.	2.4	4
638	Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: Implications for imatinib mesylate response and resistance. <i>Leukemia and Lymphoma</i> , 2006, 47, 1651-1664.	0.6	4
639	Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver " Will it hit the moving target?. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1471-1477.	1.9	4
640	Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy. <i>International Journal of Hematology</i> , 2012, 95, 1-2.	0.7	4
641	Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1265-1271.	1.1	4
642	Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients With Advanced Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 194-203.	2.3	4
643	The checklist: BEST medical center employment requirements 2015. <i>Clinics in Dermatology</i> , 2015, 33, 493-497.	0.8	4
644	Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report. <i>Journal of Medical Case Reports</i> , 2015, 9, 45.	0.4	4
645	Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 357-364.	1.1	4
646	Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. <i>Clinical Cancer Research</i> , 2017, 23, 4155-4162.	3.2	4
647	JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis. <i>Cancer Biology and Therapy</i> , 2018, 19, 664-668.	1.5	4
648	Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology. <i>Integrative Cancer Therapies</i> , 2018, 17, 1012-1015.	0.8	4

#	ARTICLE	IF	CITATIONS
649	Standardized uptake value (SUV _{max}) in ¹⁸ F-FDG PET/CT is correlated with the total number of main oncogenic anomalies in cancer patients. <i>Cancer Biology and Therapy</i> , 2020, 21, 1067-1071.	1.5	4
650	Precision oncology: the intention-to-treat analysis fallacy. <i>European Journal of Cancer</i> , 2020, 133, 25-28.	1.3	4
651	Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors. <i>European Journal of Cancer</i> , 2021, 149, 184-192.	1.3	4
652	Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2274-2279.	1.9	4
653	Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease. <i>European Journal of Haematology</i> , 2021, 107, 642-649.	1.1	4
654	Alternate Week Administration of the Farnesyltransferase Inhibitor Tipifarnib (ZARNESTRAA®; R115777) in Patients with Myelodysplastic Syndrome: Results of a Phase 1 Study.. <i>Blood</i> , 2005, 106, 2521-2521.	0.6	4
655	Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors.. <i>Blood</i> , 2007, 110, 4504-4504.	0.6	4
656	Siltuximab Reverses Muscle Wasting In Patients With Multicentric Castleman's Disease. <i>Blood</i> , 2013, 122, 4394-4394.	0.6	4
657	HHV-8-Negative, Idiopathic Multicentric Castleman Disease (iMCD): A Description of Clinical Features and Therapeutic Options through a Systematic Literature Review. <i>Blood</i> , 2014, 124, 4861-4861.	0.6	4
658	Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. <i>Oncotarget</i> , 2018, 9, 28842-28848.	0.8	4
659	MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis. <i>Blood</i> , 2019, 134, 2319-2319.	0.6	4
660	Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden. <i>Journal of Hematology and Oncology</i> , 2021, 14, 201.	6.9	4
661	Improving the Institutional Submission and Approval Process for Clinical Research Protocols in Oncology. <i>Journal of Clinical Oncology</i> , 2007, 25, 1632-1633.	0.8	3
662	Studies in target-based treatment. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1477-1477.	1.9	3
663	Warning signal: Unaware of an in absentia conviction, South African cancer specialist jailed on return to the United Arab Emirates. <i>Clinics in Dermatology</i> , 2013, 31, 128-130.	0.8	3
664	Promoting Precision Cancer Medicine through a Community-Driven Knowledgebase. <i>Journal of Personalized Medicine</i> , 2014, 4, 475-488.	1.1	3
665	Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. <i>Investigational New Drugs</i> , 2014, 32, 717-722.	1.2	3
666	My personal experiences at the BEST Medical Center: A day in the clinic—the morning. <i>Clinics in Dermatology</i> , 2016, 34, 422-425.	0.8	3

#	ARTICLE	IF	CITATIONS
667	First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor. <i>Blood</i> , 2008, 112, 4939-4939.	0.6	3
668	An Open-Label, Phase 2, Multicenter Study Of The Safety Of Long-Term Treatment With Siltuximab (an Tj ETQq0 0 0 rgBT /Overlock 10 2013, 122, 1806-1806.	0.6	3
669	Comprehensive genomic profiling to identify tumor mutational burden (TMB) as an independent predictor of response to immunotherapy in diverse cancers.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14508-e14508.	0.8	3
670	Suppressed formation of bone marrow adherent layers derived from acute myeloid leukemia patients after in vitro exposure to interleukin-4. <i>Leukemia Research</i> , 1997, 21, 519-527.	0.4	2
671	A Pilot Study of Recombinant Human Interleukin-4 Therapy of Myelofibrosis. <i>Journal of Interferon and Cytokine Research</i> , 1999, 19, 1253-1255.	0.5	2
672	Studies in target-based treatment. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2385-2385.	1.9	2
673	I have good news! You have leukemia.. <i>Clinics in Dermatology</i> , 2007, 25, 350-351.	0.8	2
674	CAT scan reveals BAT sign. <i>Lancet, The</i> , 2007, 369, 217.	6.3	2
675	Molecular analysis of chromosome 22 breakpoints in adult Philadelphiaâ€positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1987, 67, 55-59.	1.2	2
676	The Karabus Affair Speaks to Larger Issues for American Academic and Medical Centers. <i>Clinics in Dermatology</i> , 2013, 31, 325-326.	0.8	2
677	My personal experiences at the BEST Medical Center: A day in the clinicâ€the afternoon. <i>Clinics in Dermatology</i> , 2016, 34, 517-520.	0.8	2
678	Reply to â€Effective therapy for advanced basal cell carcinomaâ€. <i>Journal of the American Academy of Dermatology</i> , 2020, , .	0.6	2
679	Comparison of tissue DNA to circulating tumor DNA in patients with brain metastases.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13546-e13546.	0.8	2
680	Response to CAR-T Therapy Can be Monitored Using Genome-Wide Sequencing of Cell-Free DNA in Patients with DLBCL. <i>Blood</i> , 2020, 136, 17-17.	0.6	2
681	Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. <i>Hepato-Gastroenterology</i> , 2012, 59, 960-4.	0.5	2
682	Reply to A. Ocana et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e422-e423.	0.8	1
683	Unilateral Proptosis. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 605.	3.8	1
684	Genomic Profiling of Cancers of Unknown Primary Site. <i>JAMA Oncology</i> , 2015, 1, 542.	3.4	1

#	ARTICLE	IF	CITATIONS
685	Reply to J.J. Tao et al. Journal of Clinical Oncology, 2018, 36, 2451-2451.	0.8	1
686	Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL). Cancer Biology and Therapy, 2019, 20, 247-251.	1.5	1
687	Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine Response. Clinical Cancer Research, 2020, 26, 2434-2434.	3.2	1
688	Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden. JCO Precision Oncology, 2020, 4, 514-519.	1.5	1
689	Maternal to fetal transmission of cancer: implications for molecular tumor testing, immune regulation, and pediatric malignancies. Med, 2021, 2, 211-213.	2.2	1
690	Hyperprogression in Gastric Cancer: Is MDM2 Amplification the Dark Horse?. JCO Precision Oncology, 2021, 5, 931-932.	1.5	1
691	Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,. Blood, 2011, 118, 3959-3959.	0.6	1
692	Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients. Blood, 2013, 122, 3048-3048.	0.6	1
693	Phase I Study Using Alternate Week Administration of the Farnesyl Transferase Inhibitor R115777 (Zarnestraa, C) in Patients with Myelodysplastic Syndrome.. Blood, 2004, 104, 1436-1436.	0.6	1
694	CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) - Preliminary Results of Subjects with Castleman's Disease from a Phase 1 Study in Selected Hematological Malignancies.. Blood, 2006, 108, 2728-2728.	0.6	1
695	A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.. Blood, 2008, 112, 1009-1009.	0.6	1
696	Progression-free survival 2: Is it ready for prime time?. Cancer, 2022, 128, 1361-1362.	2.0	1
697	Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies. Npj Precision Oncology, 2022, 6, 18.	2.3	1
698	Targeted Inhibitors: Novel Strategies for Response Optimization. Seminars in Oncology, 2015, 42, 773-774.	0.8	0
699	Meir Wetzler, MD. Cancer, 2015, 121, 2106-2107.	2.0	0
700	Blood Money: The Cyril Karabus Story. Clinics in Dermatology, 2015, 33, 394-395.	0.8	0
701	Response. Journal of the National Cancer Institute, 2016, 108, djw001.	3.0	0
702	ASO Author Reflections: Circulating Tumor DNA in Peritoneal Carcinomatosis. Annals of Surgical Oncology, 2018, 25, 772-773.	0.7	0

#	ARTICLE	IF	CITATIONS
703	Waun Ki Hong (1942–2019) John Mendelsohn (1936–2019). <i>Cancer Cell</i> , 2019, 35, 157-160.	7.7	0
704	Letter responds to comment on “intention-to-treat analysis in precision oncology: A cautious interpretation”. <i>European Journal of Cancer</i> , 2020, 138, 228.	1.3	0
705	ASO Author Reflections: Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , 2020, 27, 3268-3269.	0.7	0
706	Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench. <i>Oncotarget</i> , 2021, 13, 13-15.	0.8	0
707	Distinct Biological Impact of Dephosphorylation vs Downregulation of p210Bcr-Abl: Implications for Imatinib Mesylate Response and Resistance.. <i>Blood</i> , 2004, 104, 4307-4307.	0.6	0
708	A Phase I/II Study of the Oral mTOR Inhibitor RAD001 in Patients with Advanced Hematologic Malignancies.. <i>Blood</i> , 2004, 104, 4818-4818.	0.6	0
709	Prognostic Significance of Tissue Necrosis Factor-Alpha in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes.. <i>Blood</i> , 2007, 110, 4263-4263.	0.6	0
710	Clinical Outcomes and Factors Predicting Development of Venous Thromboembolic Complications in Patients with Advanced Refractory Cancer in a Phase I Clinic: The M. D. Anderson Cancer Center Experience. <i>Blood</i> , 2008, 112, 3828-3828.	0.6	0
711	Ki-Lymphoma and Interleukin-6. <i>Annals of Internal Medicine</i> , 1998, 128, 506.	2.0	0
712	Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. <i>Blood</i> , 2016, 128, 5291-5291.	0.6	0
713	Genomic analysis of circulating tumor DNA in 442 patients with carcinoma of unknown primary: Implications for targeted therapeutics.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11511-11511.	0.8	0
714	Genomic Sequencing Reveals Complex and Actionable Molecular Profiles across Hematologic Malignancies. <i>Blood</i> , 2018, 132, 5116-5116.	0.6	0
715	In the Era of Immune Checkpoint Inhibitor Therapy, Can We Safely Expand to Patients with Immunodeficiency?. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 129-129.	0.6	0
716	Variant allele fraction of genomic alterations in circulating tumor DNA (%ctDNA) correlates with SUV in PET scan. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 307-312.	1.0	0
717	Tumor Mutational Burden and PD-L1 Expression in Hematologic Malignancies. <i>Blood</i> , 2020, 136, 15-17.	0.6	0
718	Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. <i>Discovery Medicine</i> , 2015, 19, 101-8.	0.5	0
719	Cetuximab in Patients with Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Alterations.. , 2022, 5, .		0
720	Variable Mutation Expression in Human Cancers: A “Hide-and-Seek” Mechanism Linked to Differential MHC-I Presentation Dynamics. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1219-1226.	1.9	0